Da	te:2022-8-9		
Yo	ur Name: Kun Zhu		
Ma	anuscript Title: Relation of Pl	D-L1 expression with molecu	lar aberrances in lung adenocarcinoma with solid component
Ma	anuscript number (if known)	<u>:</u>	
rel pa to rel Th ma	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, e following questions apply anuscript only. e author's relationships/act	manuscript. "Related" mea e affected by the content on necessarily indicate a bias. it is preferable that you do to the author's relationship ivities/interests should be ension, you should declare	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
	item #1 below, report all su e time frame for disclosure i		d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed) Time frame: Since the initial	planning of the work
1	All according to the according		planning of the work
T	All support for the present manuscript (e.g., funding,	_XNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ XNone	
4	Consulting fees	X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_X_	None					
6	Payment for expert testimony	_X_	None					
7	Support for attending meetings and/or travel	_X_	None					
8	Patents planned, issued or pending	_X_	None					
9	Participation on a Data Safety Monitoring Board or Advisory Board	_X_	None					
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_X_	None					
11	Stock or stock options	_X_	None					
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_X_	None					
13	Other financial or non- financial interests	_X_	None					
	ease summarize the above c	onflict	of interest in	the follow	ving box:			

Date:	2022-8-9
	e:Yining Zou
Manuscrip	ot Title: Relation of PD-L1 expression with molecular aberrances in lung adenocarcinoma with solid component
Manuscrip	ot number (if known):
related to parties wh to transpa	erest of transparency, we ask you to disclose all relationships/activities/interests listed below that are the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third nose interests may be affected by the content of the manuscript. Disclosure represents a commitment arency and does not necessarily indicate a bias. If you are in doubt about whether to list a ip/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	_XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for	_ XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
-	educational events	37	
6	Payment for expert	_ XNone	
	testimony		
7	Compant for attanding	V None	
7	Support for attending meetings and/or travel	_ XNone	
8	Patents planned, issued or	XNone	
	pending		
		77	
9	Participation on a Data	_ XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	_ XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ XNone	
42	Descint of annings and	V Name	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests		
	ease summarize the above c	onflict of interest in the fo	ellowing box:

You Ma	te:2022-8-9ur Name:Gang Chen Inuscript Title: <u>Relation of PI</u> Inuscript number (if known)	D-L1 expression with molecu	lar aberrances in lung adenocarcinoma with solid component					
rela par to	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.							
	e following questions apply nuscript only.	to the author's relationship	os/activities/interests as they relate to the current					
to me	The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.							
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)					
		Time frame: Since the initial	planning of the work					
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_XNone						

Time frame: past 36 months

X

X

None

None

None

Grants or contracts from

in item #1 above).
Royalties or licenses

Consulting fees

any entity (if not indicated

2

3

4

5	Payment or honoraria for	_ XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
-	educational events	37	
6	Payment for expert	_ XNone	
	testimony		
7	Compant for attanding	V None	
7	Support for attending meetings and/or travel	_ XNone	
8	Patents planned, issued or	XNone	
	pending		
		77	
9	Participation on a Data	_ XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	_ XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ XNone	
42	Descint of annings and	V Name	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests		
	ease summarize the above c	onflict of interest in the fo	ellowing box:

Date:_____2022-8-9_____

Yo	ur Name:Li Zhao		
Ma	nuscript Title: Relation of Pl	D-L1 expression with molecu	llar aberrances in lung adenocarcinoma with solid component
Ma	nuscript number (if known)):	
rel pa to rel The ma	ated to the content of your ries whose interests may be transparency and does not e ationship/activity/interest, e following questions apply muscript only. e author's relationships/activite epidemiology of hypertedication, even if that medication.	manuscript. "Related" mean eaffected by the content of necessarily indicate a bias. It is preferable that you do not to the author's relationshif ivities/interests should be ension, you should declare eation is not mentioned in the poort for the work reported.	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for	_ XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
-	educational events	37	
6	Payment for expert	_ XNone	
	testimony		
7	Compant for attanding	V None	
7	Support for attending meetings and/or travel	_ XNone	
8	Patents planned, issued or	XNone	
	pending		
		77	
9	Participation on a Data	_ XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	_ XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ XNone	
42	Descint of annings and	V Name	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests		
	ease summarize the above c	onflict of interest in the fo	ellowing box:

Date:_____2022-8-9_____

Yo	ur Name:Yunlan Tao			
Ma	anuscript Title: Relation of PI	D-L1 expression with molecu	ılar aberrances in lung adenocarcinoma with solid component	ţ
Ma	anuscript number (if known)):		
In rel pa to rel Th ma	the interest of transparency ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, e following questions apply anuscript only.	we ask you to disclose all manuscript. "Related" me affected by the content on necessarily indicate a bias. it is preferable that you do to the author's relationship ivities/interests should be ension, you should declare	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive	
	item #1 below, report all sup e time frame for disclosure is	• •	d in this manuscript without time limit. For all other item	ıs,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initia	l planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_None		
		Time frame: past	36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		
3	Royalties or licenses	XNone		
4	Consulting fees	_ XNone		

5	Payment or honoraria for	_ XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
-	educational events	37	
6	Payment for expert	_ XNone	
	testimony		
7	Compant for attanding	V None	
7	Support for attending meetings and/or travel	_ XNone	
8	Patents planned, issued or	XNone	
	pending		
		77	
9	Participation on a Data	_ XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	_ XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ XNone	
42	Descint of annings and	V Name	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests		
	ease summarize the above c	onflict of interest in the fo	ellowing box:

Date:_____2022-8-9_____

Yo	ur Name: Shaohua Lu			
Ma	anuscript Title: Relation of Pl	D-L1 expression with molecu	ılar aberrances in lung adenocarcinoma with solid component	ţ
Ma	anuscript number (if known)	:		
In rel to rel	the interest of transparency ated to the content of your rties whose interests may be transparency and does not i ationship/activity/interest,	r, we ask you to disclose all manuscript. "Related" me e affected by the content on necessarily indicate a bias. it is preferable that you do	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so. ps/activities/interests as they relate to the current	
to me	the epidemiology of hyperte edication, even if that medic	ension, you should declare ation is not mentioned in pport for the work reporte	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. Ed in this manuscript without time limit. For all other item	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initia	l planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_XNone		
		Time frame: past	36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ XNone		
3	Royalties or licenses	XNone		
4	Consulting fees	_ XNone		

5	Payment or honoraria for	_ XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
-	educational events	37 81	
6	Payment for expert	_ XNone	
	testimony		
7	Compant for attanding	V Name	
7	Support for attending meetings and/or travel	_ XNone	
8	Patents planned, issued or	XNone	
	pending		
		77	
9	Participation on a Data	_ XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	_ XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ XNone	
42	Descint of annings and	V None	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other services		
13	Other financial or non- financial interests	X None	
13		none	
	ease summarize the above c	onflict of interest in the fo	ollowing box:

Da	te:2022-8-9								
	our Name:Yingyong Hou								
Ma	Manuscript Title: Relation of PD-L1 expression with molecular aberrances in lung adenocarcinoma with solid component								
Ma	nuscript number (if known)):							
		·	relationships/activities/interests listed below that are						
			ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment						
-			If you are in doubt about whether to list a						
	ationship/activity/interest,	•	•						
	e following questions apply nuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>						
to		ension, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.						
	tem #1 below, report all su time frame for disclosure i	• •	d in this manuscript without time limit. For all other items,						
		Name all entities with	Specifications/Comments						
		whom you have this	(e.g., if payments were made to you or to your						
		relationship or indicate	institution)						
		none (add rows as							
		needed)							
_		Time frame: Since the initia	l planning of the work						
1	All support for the present	_XNone							
	manuscript (e.g., funding, provision of study materials,								
	medical writing, article								
	processing charges, etc.)								
	No time limit for this item.								
		Time frame: past	36 months						
2	Grants or contracts from	_ XNone							
	any entity (if not indicated								
_	in item #1 above).	V None							
3	Royalties or licenses	_ XNone							
	Consulting fees	X None							

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_X_	None					
6	Payment for expert testimony	_X_	None					
7	Support for attending meetings and/or travel	_X_	None					
8	Patents planned, issued or pending	_X_	None					
9	Participation on a Data Safety Monitoring Board or Advisory Board	_X_	None					
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_X_	None					
11	Stock or stock options	_X_	None					
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_X_	None					
13	Other financial or non- financial interests	_X_	None					
	ease summarize the above c	onflict	of interest in	the follo	wing box	(:		